{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:39:23Z","timestamp":1790397563310,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":885,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1111\/jth.14871","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T02:26:19Z","timestamp":1587695179000},"page":"1320-1323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID\u201019 respiratory syndrome patients treated with antiviral agents: The Cremona experience"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-0243","authenticated-orcid":false,"given":"Sophie","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Prandoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Morandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Tala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Dellanoce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Giorgi\u2010Pierfranceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Battista","family":"Danzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gualtiero","family":"Palareti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1111\/jth.14871_bb0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.2020.1097","article-title":"The novel coronavirus originating in wuhan, china: challenges for global health governance","volume":"323","author":"Phelan","year":"2020","journal-title":"JAMA"},{"key":"10.1111\/jth.14871_bb0015","unstructured":"World Health Organization (WHO). Coronavirus disease 2019 (COVID\u201019) Situation Report \u2013 51. 2020."},{"key":"10.1111\/jth.14871_bb0020","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence\u2010based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1111\/jth.14871_bb0025","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence\u2010based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence\u2010based clinical practice guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14871_bb0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2015.12.001","article-title":"Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics","volume":"137","author":"Testa","year":"2016","journal-title":"Thromb Res"},{"issue":"4","key":"10.1111\/jth.14871_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE\u2010LY Trial (Randomized Evaluation of Long\u2010Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.14871_bb0040","unstructured":"(EMA) EMA. Pradaxa \u2010 summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010Product_Information\/human\/000829\/WC500041059.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14871_bb0045","unstructured":"(EMA) EMA. Xarelto \u2010 Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000944\/WC500057108.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14871_bb0050","unstructured":"(EMA) EMA. Eliquis \u2010 Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002148\/WC500107728.pdf. Accessed 26 September 2017."},{"key":"10.1111\/jth.14871_bb0055","unstructured":"(EMA) EMA. Lixiana \u2010 summary of product characteristics. European Medicines Agency. Lixiana \u2010 summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002629\/WC500189045.pdf. Accessed 26 September 2017."},{"issue":"7","key":"10.1111\/jth.14871_bb0060","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jth.14457","article-title":"Palareti G; Coordinator of START2\u2010Register. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","volume":"17","author":"Testa","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1111\/jth.14871_bb0065","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high\u2010risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.14871_bb0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019\u2010nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jth.14871_bb0075","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2010ritonavir in adults hospitalized with severe Covid\u201019","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14871_bb0080","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID\u201019?","volume":"12","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1111\/jth.14871_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) and coronavirus disease\u20102019 (COVID\u201019): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/jth.14871_bb0090","article-title":"Drug\u2010drug interactions with direct oral anticoagulants","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"10.1111\/jth.14871_bb0095","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non\u2010vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1111\/jth.14871_bb0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co\u2010administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"7 Suppl","key":"10.1111\/jth.14871_bb0105","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1111\/jth.14871_bb0110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council forStandardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1111\/jth.14871_bb0115","first-page":"462","article-title":"Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL","volume":"16","author":"Tripodi","year":"2018","journal-title":"Blood Transfus"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14871","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622014532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622014532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:29:18Z","timestamp":1761535758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622014532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1538783622014532"],"URL":"https:\/\/doi.org\/10.1111\/jth.14871","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID\u201019 respiratory syndrome patients treated with antiviral agents: The Cremona experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}